Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-Current Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Non-Current Assets for 11 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets changed N/A to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $3.6 million for FY2025, N/A changed from the prior year.
  • Non-Current Assets for Q4 2025 was $3.6 million at Crescent Biopharma, down from $3.7 million in the prior quarter.
  • The five-year high for Non-Current Assets was $4.3 million in Q1 2021, with the low at $52320.0 in Q3 2024.
  • Average Non-Current Assets over 5 years is $2.4 million, with a median of $2.7 million recorded in 2022.
  • The sharpest move saw Non-Current Assets plummeted 95.61% in 2024, then surged 6983.33% in 2025.
  • Over 5 years, Non-Current Assets stood at $3.6 million in 2021, then tumbled by 69.2% to $1.1 million in 2022, then surged by 39.22% to $1.5 million in 2023, then plummeted by 96.57% to $52320.0 in 2024, then surged by 6853.36% to $3.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $3.6 million, $3.7 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.